Phentermine after gastric sleeve surgery is a topic many patients explore when weight loss stalls or regain occurs following their procedure. Whilst phentermine is a well-known appetite suppressant used in some countries, it is not licensed for use in the United Kingdom and is not available on NHS prescription. Understanding why weight loss plateaus happen, what phentermine actually is, and which evidence-based, licensed alternatives exist through NHS and private bariatric services is essential for anyone navigating post-operative weight management safely and effectively.

Why Weight Loss May Stall After Gastric Sleeve Surgery

Weight loss plateaus after gastric sleeve surgery are common and result from reduced basal metabolic rate, hormonal adaptations, possible sleeve dilation, and behavioural factors such as grazing or high-calorie liquid intake.

Gastric sleeve surgery (sleeve gastrectomy) is one of the most commonly performed bariatric procedures in the UK, reducing the stomach to roughly 15–20% of its original size. For many patients, the first 12–18 months bring significant and encouraging weight loss. However, it is not uncommon for progress to slow or plateau — sometimes well before a patient's target weight has been reached.

Several physiological factors contribute to this stall. As the body loses weight, its basal metabolic rate decreases, meaning fewer calories are burned at rest. Hormonal adaptations — including changes in ghrelin, leptin, and insulin sensitivity — can gradually increase appetite and reduce the sense of restriction that the sleeve initially provides. Over time, the stomach sleeve may also dilate slightly, allowing larger portion sizes.

Other important contributors to a plateau or weight regain include:

• Medications that promote weight gain, such as certain antipsychotics, antidepressants, corticosteroids, or insulin — a medication review with your GP or bariatric team is worthwhile

• Alcohol consumption, which adds calories and may increase in some patients after bariatric surgery

• Endocrine causes, including hypothyroidism or other hormonal conditions

• Pregnancy

• Mechanical complications, such as sleeve dilation, stricture, or severe gastro-oesophageal reflux, which require specialist assessment

Behavioural and psychological factors play an equally important role. Emotional eating, grazing between meals, or returning to high-calorie liquid foods can all undermine surgical outcomes. Research consistently shows that long-term success depends not only on the procedure itself but on sustained dietary, behavioural, and sometimes pharmacological support.

Understanding why weight loss stalls is the essential first step before considering any additional intervention — including medication. Patients experiencing a plateau are encouraged to revisit their bariatric team rather than seeking solutions independently, as the underlying cause will determine the most appropriate and safest course of action. The NHS and the British Obesity and Metabolic Surgery Society (BOMSS) both provide guidance on expected weight loss trajectories and reasons for plateau after sleeve gastrectomy.

What Is Phentermine and How Does It Work?

Phentermine is an appetite suppressant that stimulates noradrenaline release in the hypothalamus, but it is not licensed by the MHRA and is not available on NHS prescription in the UK.

Phentermine is a sympathomimetic amine that acts primarily as an appetite suppressant. It works by stimulating the release of noradrenaline in the hypothalamus, the brain region responsible for regulating hunger and satiety. This reduces appetite signals, helping individuals consume fewer calories. It may also have modest effects on dopamine and serotonin pathways, further influencing food-seeking behaviour.

Phentermine is not licensed for use in the United Kingdom. It does not hold a marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA), is not available on NHS prescription, and routine prescribing for weight management is not recommended. In limited circumstances, unlicensed medicines can be supplied in the UK through 'specials' processes; however, this route is generally inappropriate for weight management given the availability of licensed alternatives, and any such supply would require explicit clinical justification and medical oversight.

Despite this, some patients researching weight loss options — particularly those who have undergone bariatric surgery and experienced a plateau — may encounter phentermine through online pharmacies or overseas suppliers. This raises significant safety concerns, as medications obtained outside regulated UK channels carry risks including:

• Incorrect dosing or counterfeit products

• Absence of medical supervision

• Potentially dangerous drug interactions

• Unmonitored cardiovascular side effects, including raised blood pressure and heart rate

Phentermine's stimulant properties mean it is contraindicated in a number of conditions that may be relevant in post-bariatric patients, including:

• Use of monoamine oxidase inhibitors (MAOIs) within the preceding 14 days — this is an absolute contraindication due to risk of hypertensive crisis

• Moderate-to-severe or uncontrolled hypertension

• Cardiovascular disease (including coronary artery disease, arrhythmias, and heart failure)

• Hyperthyroidism

• Glaucoma

• Agitation or psychiatric instability

• History of drug or alcohol misuse

• Pregnancy or breastfeeding

Caution is also required with serotonergic medicines (such as SSRIs and SNRIs) and other stimulants due to the risk of additive cardiovascular or serotonergic effects.

Given phentermine's unlicensed status in the UK and its significant contraindication and interaction profile, patients should not attempt to source or use it without explicit guidance from a qualified medical professional. If you think you have experienced a side effect from any medicine, report it to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

Risks and Considerations Following Gastric Sleeve Procedures

Post-sleeve patients face altered drug absorption and elevated cardiovascular risk, making phentermine's stimulant effects particularly hazardous; there is no UK regulatory guidance supporting its use in this population.

Post-bariatric patients represent a clinically distinct population, and the use of any appetite-suppressing or weight-loss medication following surgery requires careful consideration. The anatomical and physiological changes brought about by a sleeve gastrectomy can significantly alter how medications are absorbed, metabolised, and tolerated.

Following sleeve gastrectomy, gastric pH and emptying rate are altered, which can affect the dissolution and absorption of oral medications — particularly those in modified-release or enteric-coated formulations. Whilst the small intestine remains the primary site of drug absorption, these upstream changes can affect the rate and extent of absorption (Tmax and Cmax). There is currently limited clinical evidence specifically examining phentermine use in post-sleeve patients, and no UK regulatory guidance endorses its use in this context. BOMSS guidance on medicines after bariatric surgery provides UK-specific advice on pharmacotherapy following sleeve gastrectomy and bypass procedures.

From a cardiovascular standpoint, phentermine's stimulant effects are a particular concern. Bariatric surgery patients may already have underlying cardiovascular risk factors such as hypertension, type 2 diabetes, or a history of obstructive sleep apnoea. Introducing a sympathomimetic agent without medical supervision could exacerbate these risks. Known adverse effects of phentermine include:

• Elevated heart rate and blood pressure

• Insomnia and restlessness

• Dry mouth and constipation

• Agitation or, rarely, psychosis

• Risk of dependence with prolonged use

• Pulmonary arterial hypertension — this is a rare and uncertain risk for phentermine used alone; the stronger evidence for this adverse effect relates to fenfluramine and fenfluramine-derivative combinations, which are no longer in use. Patients with any pre-existing cardiopulmonary conditions should be particularly cautious.

Important drug interactions include an absolute contraindication with MAOIs (within 14 days), and caution with SSRIs, SNRIs, and other sympathomimetic agents.

There is also the psychological dimension to consider. Some individuals who have undergone bariatric surgery have a history of disordered eating or complex relationships with food and body image. Stimulant-based appetite suppressants carry a risk of misuse in vulnerable populations, and this must be weighed carefully by any clinician involved in post-operative care.

In summary, the risks associated with phentermine use after gastric sleeve surgery — particularly given its unlicensed status in the UK — are considerable and should not be underestimated.

Alternatives Available Through NHS and Private Bariatric Services

Licensed UK options for post-sleeve weight management include orlistat, naltrexone/bupropion (Mysimba), and GLP-1 receptor agonists semaglutide (Wegovy) and liraglutide (Saxenda), accessible via Tier 3 or Tier 4 specialist weight management services.

For patients in the UK who are struggling with weight regain or a plateau following gastric sleeve surgery, there are evidence-based, licensed options available through both NHS and private bariatric services. These should always be the first port of call rather than unlicensed medications sourced independently.

Orlistat (brand names Xenical and Alli) is an MHRA-licensed oral weight-loss medicine. It works by inhibiting pancreatic lipase, reducing the absorption of dietary fat by approximately 30%. Whilst it can be used post-bariatric surgery in some cases, its gastrointestinal side effects — including steatorrhoea and faecal urgency — may be more pronounced in patients who have already undergone significant anatomical changes.

Experiencing these side effects? Our pharmacists can help you navigate them →

Naltrexone/bupropion (Mysimba) is also an MHRA-licensed oral option for weight management in the UK. It acts on the central nervous system to reduce appetite and food cravings. Availability may be subject to local NHS commissioning decisions, and it is not suitable for all patients — contraindications include uncontrolled hypertension, seizure disorders, and concurrent opioid use. Patients should discuss suitability with their specialist team.

GLP-1 receptor agonists, particularly semaglutide (Wegovy) and liraglutide (Saxenda), represent an increasingly utilised option. These medicines mimic the action of glucagon-like peptide-1, promoting satiety, slowing gastric emptying, and reducing caloric intake. NICE technology appraisal TA875 (2023) has approved semaglutide (Wegovy) for weight management in adults with obesity, subject to specific clinical criteria and access via specialist weight management services. Liraglutide (Saxenda) is approved under NICE TA664, also subject to defined criteria. Some bariatric centres are now incorporating GLP-1 receptor agonists into post-operative care pathways for patients experiencing weight regain, though clinical protocols and local commissioning arrangements vary. Patients should refer to the relevant Summary of Product Characteristics (SmPC) on the Electronic Medicines Compendium (EMC) for full prescribing information.

Access to these medicines in the NHS is typically through Tier 3 or Tier 4 specialist weight management services. Patients may be referred by their GP or bariatric team into these pathways, which provide multidisciplinary support alongside any pharmacological treatment. NHS England provides information on specialist weight management service access routes.

Beyond pharmacology, NHS bariatric services typically offer:

• Dietetic review and nutritional optimisation

• Psychological support and cognitive behavioural therapy (CBT)

• Structured physical activity programmes

• Consideration of revisional bariatric surgery in appropriate cases

Private bariatric clinics may offer additional options, including endoscopic procedures or more intensive medical weight management programmes. Patients are encouraged to explore these regulated pathways before considering any unlicensed alternatives.

When to Speak to Your Bariatric Team About Ongoing Weight Management

Patients should contact their bariatric team or GP if they experience a plateau lasting more than 8–12 weeks, significant weight regain, increased hunger, nutritional deficiency symptoms, or are considering any unlicensed medication.

Ongoing communication with a specialist bariatric team is one of the most important factors in achieving and maintaining long-term success after gastric sleeve surgery. Many patients are discharged from active follow-up within one to two years of their procedure, but weight management is a lifelong process, and access to specialist support should not end prematurely. BOMSS recommends structured long-term follow-up, including annual blood monitoring, for all patients who have undergone bariatric surgery.

Seek urgent medical attention if you experience any of the following after gastric sleeve surgery:

• Persistent vomiting or inability to tolerate fluids

• Dysphagia (difficulty swallowing)

• Severe or worsening abdominal pain

• Signs of gastrointestinal bleeding (e.g., blood in vomit or black stools)

• Rapid unintentional weight loss or gain

• Symptoms of severe dehydration

Contact your bariatric team or GP if you notice:

• A weight loss plateau lasting more than 8–12 weeks despite adherence to dietary and lifestyle guidance (note: thresholds may vary by service and individual circumstances)

• Significant weight regain — your bariatric team can advise on what is clinically meaningful for your situation

• Increased hunger or reduced restriction, which may indicate sleeve dilation or hormonal changes

• Symptoms of nutritional deficiency, such as fatigue, hair loss, tingling in the extremities, or low mood

• Deterioration in obesity-related conditions, such as worsening blood glucose control or rising blood pressure

• Psychological difficulties, including low mood, anxiety, or disordered eating behaviours

• Progressive or severe gastro-oesophageal reflux

Annual blood monitoring is recommended by BOMSS for all post-bariatric patients and typically includes full blood count, ferritin, vitamin B12 and folate, vitamin D, calcium, parathyroid hormone (PTH), and urea, electrolytes, and liver function tests. Micronutrient supplementation should also be reviewed regularly.

If you are considering using any medication — including those sourced online or from overseas — it is essential to discuss this with your GP or bariatric physician first. Self-prescribing unlicensed medications such as phentermine carries real clinical risk and may interact with other treatments or underlying conditions.

Worried about interactions with other medications? Speak to one of our pharmacists →

Patients who originally accessed bariatric surgery through the NHS may be able to re-engage with their surgical centre or be re-referred by their GP to Tier 3 or Tier 4 specialist weight management services. Those treated privately should contact their clinic directly. The goal is always sustainable, medically supervised weight management — not a quick fix.

If you think you have experienced a side effect from any medicine, report it to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk).

Frequently Asked Questions